{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-085858","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.327788+00:00","generated_at":"2026-05-17T07:21:34.760373+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NKGen completes acquisition of 65% stake in NKMax for ~$17M, gaining full control of manufacturing and IP","bullets":["Acquired 46.4M shares at ~$0.36/share, representing 65% interest in NKMax out of bankruptcy.","Funding of ~$17M: majority from AlpineBrook Capital GP I Limited, remainder from CEO Paul Y. Song; terms pending.","Transaction grants NKGen full control of NKMax's global manufacturing infrastructure, IP, and exclusive commercialization rights.","NKGen expects to accelerate clinical development of troculeucel (Alzheimer's therapy) and expand NK cell therapy pipeline.","NKGen stock trades on OTC Expert Market; removal of parent overhang may renew investor interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-085858","json":"https://secwatch.observer/filing/0001213900-25-085858.json","markdown":"https://secwatch.observer/filing/0001213900-25-085858.md","text":"https://secwatch.observer/filing/0001213900-25-085858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390025085858/0001213900-25-085858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390025085858/ea0256553-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:21:34.760373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9d77698593fdaeaf281c7d0113e2b87941eb64d","claim":"NKGen Biotech, Inc. completed an acquisition involving NKMax Co., Ltd. for approximately $0.36 per share (closed 2025-09-04).","evidence_excerpt":"in the Current Reports on Form 8-K filed on June 20, 2025 and December 2, 2024. The Company purchased 46,400,000 common shares of NKMax at a price per share of approximately $0.36. This transaction grants the Company full control over NKMax’s global manufacturing infrastructure, intellectual property (“IP”), and exclusive commercialization rights. The","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390025085858/0001213900-25-085858-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"NKMax Co., Ltd."},{"label":"Consideration","value":"approximately $0.36 per share"},{"label":"Closing","value":"2025-09-04"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}